Ipsen’s Kayfanda® (odevixibat) approved in European Union...
PARIS, FRANCE, 23 September, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission has approved Kayfanda® (odevixibat) under exceptional circumstances for the treatment of cholestatic pruritus in Alagille Syndrome ...